Jemal Alemu

Background: Flow cytometric characterisation of acute leukaemia is a key diagnostic approach for clinical management of patients, but is minimally practised in resource-constrained settings like Ethiopia.Objective: This study aimed to determine the immunophenotypes of acute leukaemia by flow cytometry at Tikur Anbessa Specialised Hospital, Addis Ababa, Ethiopia.Methods: A cross-sectional study was conducted on adolescent and adult inpatients consecutively admitted from April 2019 to June 2021. Peripheral blood samples were stained for surface and cytoplasmic markers, and analysed by four-colour flow cytometry.Results: Of 140 cases aged 13 years to 76 years, 74 (53%) were men and 66 (47%) were women, 68 (49%) had acute lymphocytic leukaemia (ALL), 65 (46 %) had acute myelogenous leukaemia (AML), and 7 (5.0%) had acute leukaemia non-otherwise specified. Acute lymphocytic leukaemia was more common among adolescent and male cases; AML was more common among adult and female cases. Among ALL subtypes, B-cell acute lymphocytic leukaemia cases (73.5%) were more common than T-cell acute lymphocytic leukaemia (26.5%). A subset of acute leukaemia, CD19+/CD56+ AML was identified in 3 cases (6% of AML). Of the B-cell ALL cases, 21 (42%) were CD34+/CD10+/CD66c+, 10% were CD34+/CD10+/CD66c–, 32% were CD34-/CD10+, and 6% were CD34+/CD10–. An unexpectedly high number of T-cell ALL cases that lacked surface CD3 were observed to have significantly higher levels of aberrantly expressed myeloid markers.Conclusion: We observed multiple phenotypes identifying subtypes of acute leukaemia cases, extending our previous studies in Ethiopia.What this study adds: This study extends previous studies by describing phenotypically defined subsets of ALL and AML which, in addition to diagnosis, may have useful prognostic value for clinicians.

SARS-CoV-2 and blood-borne viral coinfections are well reported. Nevertheless, little is known regarding the seroprevalence of SARS-CoV-2 and coinfection with blood-borne viruses in hematologic malignancy patients in Ethiopia. We aimed to assess the seroprevalence of SARS-CoV-2 and associated infections with hepatitis B and other viruses among adolescent and adult acute leukemia patients at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. A cross-sectional study was conducted from July 2020 to June 2021. Blood samples were tested for the presence of anti-SARS-CoV-2, HBV, HCV, and HIV with ELISA kits and occult hepatitis B infection with a real-time polymerase chain reaction assay. Out of a total 110 cases, the SARS-CoV-2 seroprevalence was 35.5%. The prevalence showed a significant increment from July 2020 to the end of June 2021 (p = 0.015). In 22.7% and 2.7% of leukemia cases, HBV and HIV, respectively, were detected. No HCV was identified. The rate of SARS-CoV-2 coinfection with HBV and HIV was 28% (11/39) and 2.6% (1/39), respectively; however, there was no statistically significant association between SARS-CoV-2 seropositivity with HBV and HIV (p > 0.05). There is a need for viral screening in leukemia cases to monitor infections and inform management.

Leukemic patients are prone to infectious agents such as viruses due to dysregulated immune system resulting from infiltration of the bone marrow by malignant cells, chronic stimulation, reactivation of some viruses and viral pathogenicity as well as rarely from acquisition of a new infections leading to severe complications. However, the prevalence of these infections has not been systematically documented in resource-limited settings such as Ethiopia. To determine the prevalence of HBV, HCV, and HIV among adult and adolescent in-patients with acute leukemia before the administration of chemotherapy, at the Tikur Anbessa Specialized Hospital (TASH) in Addis Ababa, Ethiopia. A cross sectional study was conducted on 176 adult and adolescent inpatient Ethiopians, who were diagnosed with acute leukemia from April 2019 to June 2021. Socio-demographic characteristics and relevant clinical data were collected. Peripheral blood samples were collected and tested for HBV, HIV, and HCV using Enzyme-Linked Immunosorbent Assay (ELISA) and real-time PCR. Chi-square tests were used to assess associations between variables. Of the 176 patients, 109(62%) were males. The median age was 25[IQR,18–35] yr, with a range from 13 to 76 year. The prevalence of HBV (positivity for HBsAg plus HBV DNA), HCV and HIV was 21.6%, 1.7%, and 1.7%, respectively. HBsAg was positive in 19 cases (10.8%). Among 157 HBsAg negative patients, 52(33.1%) were positive for Anti-HBcAg; of these seropositive cases, 47.5% were positive for HBV DNA. Most DNA positive, HBsAg negative cases (79.0%) had DNA concentrations below 200 IU/ml indicating true occult HBV infection (OBI). Of the 176 cases, 122 had a history of blood transfusions, but no statistically significant association was found between HBV infection and blood product transfusion history (P = 0.963). The prevalence of HBV, HIV and HCV in patients with acute leukemia was similar to the national prevalence level of these infections. Given the HBsAg positivity and the high prevalence of occult hepatitis B infection in our study, these patients may be at increased risk for chemotherapy related hepatitis flares. Hence, clinicians caring these patients are strongly advised to screen their patients for HBV and also for HIV and HCV infections routinely.